As the United States just recently approved its first biosimilar, Novartis’ Zarxio, pharmacy benefit managers (PBMs) are already seeking steep discounts from the biosimilars industry. How big of a role will PBMs play in the US biosimilar market? See more here. (Source: Duncan Emerton, FirstWord Pharma, 4//8/15)
You are here: / / What Discounts Will US Pharmacy Benefit Managers See From Biosimilars?